Healthcare Private Placement and M&A Transactions Review

Strategy | Financing | Macro & Markets

Share Silverwood Weekly Healthcare Market Update

Private Placement / Financing Transactions

Ollin: The company raised $330 million of Series B venture funding in a deal led by ARCH Venture Partners and TCG Crossover Management on June 24, 2026, putting the company’s pre-money valuation at $507 million. The company is a developer of ophthalmic therapeutics designed to treat vision-threatening eye diseases.Radiology Partners: The company received $268.5 million of development capital from undisclosed investors on June 23, 2026. The company is an operator of multi-state onsite radiology centers for radiologists, radiology practices, hospitals, health systems, patients and families.Osanni Bio: The company raised $190 million of Series B venture funding in a deal led by Patient Square Capital on June 23, 2026. The company is a developer of therapeutics focused on ophthalmology, cardiology and other disease areas.Bionyra: The company raised $165 million of Series A venture funding in a deal led by Jeito and Sofinnova Partners on June 22, 2026. The company is a biotechnology developer of antibody-based therapies for immune and inflammatory diseases.Lycia Therapeutics: The company raised $75 million of Series D venture funding in a deal led by Janus Henderson Investors and Balyasny Asset Management on June 25, 2026. The company is a biotechnology developer of extracellular protein degradation therapies for disease-causing proteins.Assort Health: The company raised $120 million of Series C venture funding in a deal led by Menlo Ventures on June 24, 2026, putting the company’s pre-money valuation at $1 billion. The company is a developer of healthcare voice AI software for automating patient scheduling, referrals, intake and follow-up calls.RQ Bio: The company raised $115 million of Series A venture funding in a deal led by Frazier Healthcare Partners on June 24, 2026. The company is a developer of monoclonal antibody medicines for infectious disease protection.Cadence: The company raised $100 million of Series C venture funding in a deal led by Spark Capital on June 23, 2026, putting the company’s pre-money valuation at $1.15 billion. The company is an operator of a remote care platform for monitoring and managing chronic conditions at home.Quanta Therapeutics: The company raised $76.1 million of Series D venture funding in a deal led by Avidity Partners on June 24, 2026, putting the company’s pre-money valuation at $180 million. The company is a developer of therapeutic drugs designed to treat RAS-driven cancers.Nura Bio: The company raised $73.8 million of Series B venture funding in a deal led by The Column Group on June 22, 2026. The company is a biotechnology developer of neuroprotective therapies targeting axon degeneration and neuroimmune regulation in neurological diseases.TISSIUM: The company raised EUR 60 million of Series D venture funding through a combination of debt and equity on June 24, 2026. The company is a developer of biomorphic programmable polymers for tissue reconstruction across multiple surgical applications.Oblenio Bio: The company raised $62 million of Series B venture funding in a deal led by Pfizer Ventures on June 25, 2026. The company is a developer of therapies for severe autoimmune diseases.Saturnus Bio: The company raised $50 million of venture funding from Merck on June 24, 2026. The company is a developer of therapeutic pharmaceuticals and biological therapies intended to prevent and treat cardiovascular and muscle diseases.xCures: The company raised $46 million of Series B venture funding in a deal led by Innovius Capital Management on June 24, 2026. The company is a developer of an AI-assisted clinical data platform designed to replace manual processes for acquiring, reading, and re-entering medical records.CroiValve: The company raised $27 Million of Series B venture funding in a deal led by Medtech Syndicate Nominee on June 23, 2026. The company is a developer of minimally invasive heart valve devices designed to treat severe tricuspid regurgitation.NorthLinks Bio: The company raised $34 million of venture funding from RA Capital Management on June 23, 2026. The company is a biotechnology developer of intranasal antiviral medicines for broad respiratory virus protection.Prosper AI: The company raised $30 million of Series A venture funding in a deal led by Andreessen Horowitz on June 22, 2026, putting the company’s pre-money valuation at $174 million. The company is a developer of healthcare voice AI agents for patient access, payer calls and revenue cycle workflows.Credence MedSystems: The company raised $23.5 million of Series C venture funding from Novartis on June 22, 2026, putting the company’s pre-money valuation at $196.5 million. The company is a developer of injectable drug delivery devices for pharmaceutical and biotechnology applications.Nanoflex Robotics: The company raised EUR 10 million of venture funding from European Innovation Council on June 24, 2026. The company is a developer of magnetic navigation-based telerobotic systems for remote endovascular procedures.TomBot: The company raised $7 million of Series A3 venture funding from Wavemaker Three-Sixty Health, Caduceus Capital Partners and Florida Community Health Network on June 25, 2026. The company is a developer of robotic companion animals for dementia care and emotional support.ARMR Sciences: The company raised venture funding from SRX Global and other undisclosed investors on June 23, 2026. The company is a developer of biodefense therapeutics designed to provide preventive protection against synthetic drug threats. The company is a developer of preventive biodefense therapeutics for protection against synthetic drug and bioweapon threats.DropGenie: The company raised an undisclosed amount of venture funding in a deal led by Skeleton Key Management on June 22, 2026. The company is a developer of microfluidics-based systems for miniaturizing and automating synthetic biology workflows.

M&A Transactions

Bio-Techne / Merck: The company reached a definitive agreement to be acquired by Merck for approximately $11.3 billion on June 25, 2026. The company is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets.Apogee Therapeutics / AbbVie: The company reached a definitive agreement to be acquired by AbbVie for $10.9 billion on June 22, 2026. The company is a developer of clinical-stage biologic therapies for inflammatory and immunology diseases.Centessa Pharmaceuticals / Lilly USA: The company was acquired by Lilly USA for $7.8 billion on June 24, 2026. The company is a developer of clinical-stage orexin-based neuroscience therapies.Kelonia / Lilly USA: The company was acquired by Lilly USA for $7 billion on June 26, 2026. The company is a developer of targeted genetic medicine delivery systems.Biocare Medical / Agilent Technologies: The company was acquired by Agilent Technologies for $950 million on June 25, 2026. The company is a developer and manufacturer of immunohistochemistry and molecular diagnostic reagents for clinical and research laboratories.Advanced Medical Solutions Group / H.B. Fuller: The company is in talks to be acquired by H.B. Fuller for approximately $942 million on June 25, 2026. The company is a developer and manufacturer of wound care and surgical tissue-healing products.Humaskan / Davion Healthcare: The company reached a definitive agreement to be acquired by Davion Healthcare for $60 million on June 25, 2026. The company is a manufacturer of medical devices designed for non-invasive home testing and remote health monitoring.Sanmirna Therapeutics / Thalia Therapeutics: The company was acquired by Thalia Therapeutics for EUR 3.6 million on June 24, 2026. The company is a developer of microRNA-based therapeutics designed to target leukemia stem cells.Acquis BI / Health Tequity: The business unit of Acquis BI was acquired by Health Tequity for an undisclosed amount on June 22, 2026. The company is a provider of a cloud-based healthcare integration platform designed for patient data management.Bap Medical / Smile Invest: The company was acquired by Smile Invest through an LBO on June 25, 2026 for an undisclosed amount. The company is a manufacturer of medical devices intended to treat skin conditions and respiratory problems.BioMeca / Tentamus Group: The company was acquired by Tentamus Group, via its financial sponsor BC Partners, through an LBO on June 23, 2026 for an undisclosed amount. The company is a provider of biomechanical testing and high-resolution imaging services for cosmetics and pharmaceutical customers.Biosency / Withings: The company was acquired by Withings for an undisclosed amount on June 23, 2026. The company is a developer of a medical device designed to monitor and prevent respiratory failures.Boundless Bio / Serapha Bio: The company reached a definitive agreement to be acquired by Serapha Bio for an undisclosed amount on June 23, 2026. The company is a developer of cancer therapies targeting extrachromosomal DNA in oncogene-amplified tumors.ENDRA Life Sciences / Noble Africa: The company reached a definitive agreement to be acquired by Noble Africa through a reverse merger, resulting in the combined entity trading on the Nasdaq Stock Exchange under the ticker symbol “NOBA” on June 25, 2026. The company is a developer of thermo-acoustic enhanced ultrasound technology for clinical diagnostic imaging.HeartSciences / Fortitude Mining: The company reached a definitive agreement to be acquired by Fortitude Mining through a reverse merger, resulting in the combined entity trading on the Nasdaq under the ticker symbol “TUDE” on June 23, 2026. The company is a developer of AI-enabled ECG technology for earlier detection of heart disease.Padoa / Multiple Investors: The company was acquired by Five Arrows Managers, Kamet Ventures, Thoma Bravo and its management through an LBO on June 24, 2026 for an undisclosed amount. The company is a developer of occupational health software for medical monitoring and workplace prevention services.Passage Bio / Remix Therapeutics: The company reached a definitive agreement to be acquired by Remix Therapeutics through a reverse merger, resulting in the combined entity trading on the Nasdaq under the ticker symbol RMTX on June 24, 2026. The company is a developer of clinical-stage genetic medicines focused on improving the lives of patients with neurodegenerative diseases.PiezoBioMembrane / PetVivo Holdings: The company reached a definitive agreement to be acquired by PetVivo Holdings for an undisclosed amount on June 24, 2026. The company is a developer of biodegradable piezoelectric nanofiber materials for regenerative medicine applications..Validic / ChartSpan: The company was acquired by ChartSpan for an undisclosed amount on June 22, 2026. The company is a developer of healthcare data connectivity software for collecting and integrating personal health data.

Source: Pitchbook Data, Inc.
Connect on LinkedIn with Jonathan Hodson-Walker